Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.
PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.
PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.
Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.
Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.
PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.
PAVmed Inc. (PAVM, PAVMZ) has scheduled a business update conference call for March 29, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company’s growth strategy and financial results for Q4 2021. PAVmed operates in medical devices and diagnostics, with major products like EsoGuard® and EsoCheck® for early esophageal cancer detection. The call will also provide insights on upcoming milestones and market strategies. For live access, listeners may dial designated numbers or visit the company’s investor relations page.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call on March 28, 2022, at 4:30 PM EDT, featuring CEO Lishan Aklog and CFO Dennis McGrath discussing growth strategies and financial results for Q4 2021. Lucid focuses on preventing esophageal cancer through its EsoGuard® test for patients with gastroesophageal disease (GERD). The company is awaiting regulatory approval for its diagnostic products, which are crucial for its future operations and potential market acceptance.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced participation at the LSI ’22 Emerging Medtech Summit on March 15-18, 2022. Chairman and CEO Dr. Lishan Aklog will present on March 17 at 3:15 p.m. PT, focusing on cancer prevention through their EsoGuard® Esophageal DNA Test, specifically for patients at risk of esophageal cancer due to GERD. Lucid, a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), aims to enhance early detection methods with innovative diagnostics. The company is also developing a network of Lucid Test Centers for accessible testing.
Lucid Diagnostics Inc. (NASDAQ: LUCD) has launched a new subsidiary, LucidDx Labs, which now operates its own CLIA-certified laboratory in Lake Forest, CA, for conducting the EsoGuard® Esophageal DNA Test. This milestone is critical for simplifying billing processes and creating a scalable infrastructure for the growing demand for early detection of esophageal cancer. EsoGuard's effectiveness is supported by a study demonstrating over 90% sensitivity and specificity. LucidDx Labs will continue collaborating with ResearchDx for management support, further solidifying Lucid's commitment to cancer prevention.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will have Dr. Lishan Aklog, Chairman and CEO, speak at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference on February 17, 2022, at 8:00 AM EST. Lucid, a cancer prevention diagnostics company, is focused on patients with gastroesophageal disease (GERD) who are at risk for esophageal precancer. Their EsoGuard® Esophageal DNA Test is the first widely available screening tool for early detection of esophageal precancer. Lucid aims to build Lucid Test Centers for the EsoCheck procedure.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) and its subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) have established a full-time investor relations team. Adrian K. Miller has been appointed Vice President, focusing on institutional investors, while D.A. Wallace takes on the role of Director for retail relations. This move aims to enhance communication with shareholders during a rapid growth phase. Both Miller and Wallace bring extensive experience in investor relations, indicating a strategic effort to improve transparency and investor engagement.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will have Chairman and CEO Lishan Aklog speak at the 24th Annual Needham Virtual Growth Conference on January 11, 2022, at 11:30 AM EST. The discussion will focus on Lucid's cancer prevention diagnostic solutions, particularly the EsoGuard® test, designed for GERD patients at risk for esophageal cancer. This test, along with the EsoCheck® device, is crucial for early detection and has received FDA Breakthrough Device designation. The event can be accessed via Lucid's Investor Relations website.
Lucid Diagnostics has launched the EsoGuard Telemedicine Program in collaboration with UpScriptHealth, allowing chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas to access video consultations for Esophageal precancer screening. Through this program, patients can receive referrals for EsoGuard testing, aimed at early detection of esophageal cancer. The campaign will begin in Phoenix, leveraging various media channels to educate patients about the risks of esophageal cancer and the availability of EsoGuard testing.
Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, announced that CFO Dennis McGrath will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. Lucid focuses on gastroesophageal disease patients at risk of esophageal cancer, offering the EsoGuard Esophageal DNA Test alongside the EsoCheck device. Both are aimed at early cancer detection, with EsoGuard currently marketed as a Laboratory Developed Test in the U.S.
PAVmed Inc. and its subsidiary Lucid Diagnostics have provided a joint business update, announcing preliminary financial results for the six and nine months ended September 30, 2021. Both companies have recognized revenue for the first time, with PAVmed holding a 76% stake in Lucid post-IPO. Lucid raised $70 million through an IPO, and both companies collectively hold over $90 million in cash. Operating expenses for PAVmed were approximately $13.7 million, while Lucid reported $6.6 million in operating expenses. The report highlights expansions in workforce and infrastructure.
FAQ
What is the current stock price of PAVmed (PAVM)?
What is the market cap of PAVmed (PAVM)?
What does PAVmed Inc. do?
What are PAVmed's main products?
What is EsoGuard?
Who leads PAVmed Inc.?
What recent achievements has PAVmed made?
What is Veris Health?
How does PAVmed enhance value creation?
What areas does PAVmed operate in?
How can I access PAVmed's latest updates?
Where can I find more information about PAVmed?
